BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Galindo RJ, Parkin CG, Aleppo G, Carlson AL, Kruger DF, Levy CJ, Umpierrez GE, McGill JB. What's Wrong with This Picture? A Critical Review of Current Centers for Medicare & Medicaid Services Coverage Criteria for Continuous Glucose Monitoring. Diabetes Technol Ther 2021. [PMID: 33844588 DOI: 10.1089/dia.2021.0107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Peek ME, Thomas CC. Broadening Access to Continuous Glucose Monitoring for Patients With Type 2 Diabetes. JAMA 2021;325:2255-7. [PMID: 34077505 DOI: 10.1001/jama.2021.6208] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Martens TW. Continuous glucose monitoring in primary care - are we there? Curr Opin Endocrinol Diabetes Obes 2022;29:10-6. [PMID: 34845158 DOI: 10.1097/MED.0000000000000689] [Reference Citation Analysis]
3 Isaacs D, Bellini NJ, Biba U, Cai A, Close KL. Health Care Disparities in Use of Continuous Glucose Monitoring. Diabetes Technol Ther 2021;23:S81-7. [PMID: 34546086 DOI: 10.1089/dia.2021.0268] [Reference Citation Analysis]
4 Tanenbaum ML, Commissariat PV. Barriers and Facilitators to Diabetes Device Adoption for People with Type 1 Diabetes. Curr Diab Rep 2022. [PMID: 35522355 DOI: 10.1007/s11892-022-01469-w] [Reference Citation Analysis]
5 Tanenbaum ML, Messer LH, Wu CA, Basina M, Buckingham BA, Hessler D, Mulvaney SA, Maahs DM, Hood KK. Help when you need it: Perspectives of adults with T1D on the support and training they would have wanted when starting CGM. Diabetes Res Clin Pract 2021;180:109048. [PMID: 34534592 DOI: 10.1016/j.diabres.2021.109048] [Reference Citation Analysis]
6 Pauley ME, Berget C, Messer LH, Forlenza GP. Barriers to Uptake of Insulin Technologies and Novel Solutions. Med Devices (Auckl) 2021;14:339-54. [PMID: 34803408 DOI: 10.2147/MDER.S312858] [Reference Citation Analysis]
7 Bailey R, Donthi S, Markt S, Drummond C, Cullen J. Evaluating Factors Associated With Continuous Glucose Monitoring Utilization With the Type 1 Diabetes Exchange Registry. J Diabetes Sci Technol 2022;:19322968221091299. [PMID: 35506181 DOI: 10.1177/19322968221091299] [Reference Citation Analysis]
8 Bailey R, Calhoun P, Chao C, Walker T. With or without residual C-peptide, patients with type 2 diabetes realize glycemic benefits from real-time continuous glucose monitoring. Diabetes Technol Ther 2021. [PMID: 34704817 DOI: 10.1089/dia.2021.0384] [Reference Citation Analysis]
9 Wright EE, Subramanian S. Evolving Use of Continuous Glucose Monitoring Beyond Intensive Insulin Treatment. Diabetes Technol Ther 2021;23:S12-8. [PMID: 34546082 DOI: 10.1089/dia.2021.0191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kompala T, Wong J, Neinstein A. Diabetes Specialists Value CGM Despite Challenges in Prescribing and Data Review Process. J Diabetes Sci Technol 2022;:19322968221088267. [PMID: 35403469 DOI: 10.1177/19322968221088267] [Reference Citation Analysis]